Metaproscaline
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Metaproscaline (MP), also known as 3,4-dimethoxy-5-propoxyphenethylamine, is a chemical compound of the phenethylamine and scaline families related to mescaline.[1][2][3][4] It is the derivative of mescaline in which the methoxy group at the 3 position has been replaced with a propoxy group.[1][2][3][4] In addition, it is a positional isomer of proscaline.[1][2][3][4]
- None
 | |
| Clinical data | |
|---|---|
| Other names | MP; 3,4-Dimethoxy-5-propoxyphenethylamine; 3-Propoxy-4,5-dimethoxyphenethylamine |
| Routes of administration | Oral[1] |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | Unknown[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C13H21NO3 |
| Molar mass | 239.315 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
In his book PiHKAL (Phenethylamines I Have Known and Loved) and other publications, Alexander Shulgin lists metaproscaline's dose as greater than 240 mg orally and its duration as unknown.[1][2][3] The drug produced no clear effects at tested doses of up to 240 mg orally.[1]
The chemical synthesis of metaproscaline has been described.[1] Analogues of metaproscaline include mescaline, proscaline, and metaescaline, among others.[1][2][3][4]
Metaproscaline was first described in the scientific literature by Shulgin and Peyton Jacob III in 1984.[4] Subsequently, it was described in greater detail by Shulgin in PiHKAL in 1991.[1] The drug is not a controlled substance in Canada as of 2025.[5]